ESTABLISHMENT OF A BORTEZOMIB-RESISTANT CELL LINE KM3/BTZ

被引：0
|
作者：
Yedi, P. [1 ]
Luqun, W. [1 ]
机构：
[1] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Shandong, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B1487
引用
收藏
页码：594 / 594
页数：1
相关论文
共 50 条
  • [21] A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax
    Sondra L. Downey-Kopyscinski
    Sriraja Srinivasa
    Alexei F. Kisselev
    Scientific Reports, 12
  • [22] Human cytomegalovirus protects multiple myeloma cell line KM3 cells from apoptosis induced by growth factor withdrawal
    魏国庆
    林茂芳
    黄河
    蔡真
    中华医学杂志(英文版), 2004, (06) : 103 - 107
  • [23] Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma
    Corentin Bouvier
    Maria Gonzalez-Santamarta
    Núria Profitós-Pelejà
    Marc Armengol
    Grégoire Quinet
    Quentin Alasseur
    Laurie Ceccato
    Wendy Xolalpa
    Raimundo Freire
    Julie Guillermet-Guibert
    Karine Reybier
    Anne-Marie Caminade
    Hans C. Beck
    Ana Sofia Carvalho
    Rune Matthiesen
    Jean Christophe Rain
    James D. Sutherland
    Rosa Barrio
    Gaël Roué
    Manuel S. Rodriguez
    Cell Death Discovery, 11 (1)
  • [24] Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
    A Moros
    V Rodríguez
    I Saborit-Villarroya
    A Montraveta
    P Balsas
    P Sandy
    A Martínez
    A Wiestner
    E Normant
    E Campo
    P Pérez-Galán
    D Colomer
    G Roué
    Leukemia, 2014, 28 : 2049 - 2059
  • [25] Establishment and characterization of an abrin-resistant cell line
    Ko, JL
    Lin, JY
    CELL BIOLOGY AND TOXICOLOGY, 1997, 13 (02) : 75 - 81
  • [26] Establishment and characterization of an abrin-resistant cell line
    J.-L. Ko
    J.-Y. Lin
    Cell Biology and Toxicology, 1997, 13 : 75 - 81
  • [27] Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
    Moros, A.
    Rodriguez, V.
    Saborit-Villarroya, I.
    Montraveta, A.
    Balsas, P.
    Sandy, P.
    Martinez, A.
    Wiestner, A.
    Normant, E.
    Campo, E.
    Perez-Galan, P.
    Colomer, D.
    Roue, G.
    LEUKEMIA, 2014, 28 (10) : 2049 - 2059
  • [28] hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10
    Xi, Hao
    Li, Lu
    Du, Juan
    An, Ran
    Fan, Rong
    Lu, Jing
    Wu, Yin-Xiang
    Wu, Shu-Xie
    Hou, Jian
    Zhao, Li-Ming
    ONCOLOGY REPORTS, 2017, 37 (02) : 961 - 968
  • [29] Bortezomib-resistant pediatric acute myeloid leukemia cell lines derived from Down syndrome patients are sensitive to disulfiram
    Bista, Ranjan
    Pepper, Oliver
    Lee, David W.
    Azorsa, David A.
    Arceci, Robert J.
    Aleem, Eiman
    CANCER RESEARCH, 2016, 76
  • [30] Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
    De Wilt, Leonie
    Sobocki, Bartosz Kamil
    Jansen, Gerrit
    Tabeian, Hessan
    de Jong, Steven
    Peters, Godefridus J.
    Kruyt, Frank
    CANCER DRUG RESISTANCE, 2024, 7
12345